2. Search Result
Search Result
Results for "

LPA Receptor Activator

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137862
    1-Oleoyl lysophosphatidic acid
    1 Publications Verification

    1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA

    		 LPL Receptor Neurological Disease
    1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .
    1-Oleoyl lysophosphatidic acid
  • HY-13285
    Ki16425
    Maximum Cited Publications
    9 Publications Verification

    Debio 0719

    		 LPL Receptor YAP Neurological Disease Cancer
    Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .
    Ki16425
  • HY-107614
    1-Oleoyl lysophosphatidic acid sodium
    1 Publications Verification

    1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

    		 LPL Receptor Mitosis Neurological Disease
    1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a LPA receptor activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .
    1-Oleoyl lysophosphatidic acid sodium
  • HY-175084
    1-Hexadecyl lysophosphatidic acid sodium

    1-Hexadecyl LPA sodium; 1-Palmityl LPA sodium; LPA O-16:0 sodium

    		 LPL Receptor Metabolic Disease
    1-Hexadecyl lysophosphatidic acid (1-Hexadecyl LPA) sodium, an ether analog of lysophosphatidic acid (LPA), is a LPA receptor activator .
    1-Hexadecyl lysophosphatidic acid sodium
  • HY-W923661
    1-Octadecyl lysophosphatidic acid

    PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA

    		 LPL Receptor Others
    1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .
    1-Octadecyl lysophosphatidic acid
  • HY-13285R
    Ki16425 (Standard)

    		LPL Receptor YAP Neurological Disease Cancer
    Ki16425 (Standard) is the analytical standard of Ki16425. This product is intended for research and analytical applications. Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .
    Ki16425 (Standard)
  • HY-137862A
    (Rac)-1-Oleoyl lysophosphatidic acid

    (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA

    		 LPL Receptor Drug Isomer Neurological Disease
    (Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the LPA receptors .
    (Rac)-1-Oleoyl lysophosphatidic acid
  • HY-157693
    C18:1 Cyclic LPA

    		Endogenous Metabolite Cancer
    C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.
    C18:1 Cyclic LPA
  • HY-119013
    VPC32183

    		Endogenous Metabolite Cardiovascular Disease
    VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes .
    VPC32183

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: